Breaking News

Trials & Filings in Brief: Oct. 31, 2013

By Gil Roth | October 31, 2013

Ariad, Baxter, e-Therapeutics, Hyperion, Kamada, Mesoblast, Stem Cell Therapeutics, Teva

Phase I
Kamada reports preliminary pediatric diabetes data . . . read more

Phase II
e-Therapeutics starts trial of tramadol CR formulation . . . read more

Phase III
Teva gets approval for CHF trial . . . read more

Post-Approval
Hyperion begins UCD outcomes study . . . read more

Filings
Ariad suspends Iclusig marketing in U.S. . . . read more

Baxter submits Rixubis in EU . . . read more

Stem Cell Therapeutics gets Orphan status for tigecycline in AML . . . read more

blog comments powered by Disqus